Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Ongoing debates

Special report

Community pharmacy cuts

On 21 March, the UK High Court will consider two legal actions against the government’s decision to cut community pharmacy funding. The joint hearing will consider cases put forward by the Pharmaceutical Services Negotiating Committee (PSNC) and the National Pharmacy Association (NPA). Follow the judicial review with The Pharmaceutical Journal’s special report on community pharmacy cuts.

Read on

Clare Gerada, GP and chairman of Clinical Board, Primary Care Transformation, NHS England (London Region)

Q&A: How do GPs view the role of pharmacists in the NHS?Subscription

19 FEB 2015By

London-based GP Clare Gerada is chairman of Clinical Board, Primary Care Transformation, NHS England (London Region). But she is probably best known for her work as chairman of the Council of the Royal College of General Practitioners, a post she held for three years. She shares her thoughts on the role pharmacy should play in UK healthcare.

According to suggestions from the latest Nuffield Trust report "Now more than ever" community pharmacists must shift their core activities away from dispensing function towards a more clinical role

Dispensing: it’s time to let it goSubscription

29 JAN 2015By

If the aspirations of pharmacy fulfilling a clinical role integral to public healthcare is ever to be realised, community pharmacists must shift their focus away from dispensing and towards providing health services.

Community pharmacists disappointed with settlement on new pharmacy contract

Community pharmacies to lose out in new £2.8bn funding dealSubscription

22 SEP 2014By

The settlement includes £2bn, which will be delivered in fees and allowances, with the remaining £800m to be delivered through agreed drug purchase margins.  

Reader's comment

The ongoing negotiations in a similar deal, the Transatlantic Trade & Investment Partnership (TTIP) between the US and EU are also being held in secret are something we in the UK should be very wary about. Intellectual property and medicinal regulation are also being discussed which means we should take interest but the lack of attention in the mainstream media and clandestine nature of the talks prove there are things the lobbyists and negotiators don't want us to know about.

Mark Bury Free trade agreements play a dangerous game with public health